Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-06-16 | Cary Claiborne (61) has served on the Board of Directors of NeuroSense Therapeutics since December 2021, where he also serves as chair of the audit committee. Mr. Claiborne has served as the Chief Operating Officer since December 2021 and a director since November 2021 for Adial Pharmaceuticals Inc. a public biopharmaceutical company. ... The Board of Directors intends to appoint Mr. Claiborne, the Class I director nominee, as Chair of the Compensation Committee following the Annual Meeting. |
| 2023-07-28 | Cary Claiborne (62) was appointed to serve as a director of our Company in July 2022. ... Mr. Claiborne is Chairman of the Compensation Committee. ... The following table sets forth the compensation paid to our directors other than our Chief Executive Officer for the year ended December 31, 2022: ... Cary Claiborne, Director, Fees Earned or Paid in Cash ($): 31,000, Total ($): 31,000. |
| 2024-08-20 | Cary Claiborne (63) was appointed to serve as a director of our Company in July 2022. ... The following table sets forth information concerning our current directors and executive officers: ... Cary Claiborne 63 Director ... The following table provides information concerning the current membership of our Board committees: ... Mr. Cary Claiborne Chair Compensation Committee ... The following table sets forth the compensation paid to our directors other than our Chief Executive Officer for the year ended December 31, 2023: ... Cary Claiborne, Director 87,760 |
Data sourced from SEC filings. Last updated: 2025-12-06